Immunovia Publishes Interim Report for January-June 2024

April-June 2024 · Net sales, consisting of royalties, amounted to 85 KSEK (412) · Net earnings amounted to -25.6 MSEK (-185.1), where one-off costs second quarter 2023 of 141 MSEK impact comparability between the years. · Earnings per share before and after dilution were -0.57 SEK (-4.00). · Cash Flow from operating activities amounted to -28.2 MSEK (-43.3). · Cash and equivalents at the end of the period amounted to 36.8 MSEK (143.9). · The successful development of accurate and precise assays to measure targeted proteins for the next-generation test was announced on